Interactive Decision Aid for Men Diagnosed With Prostate Cancer

NCT ID: NCT04260737

Last Updated: 2024-04-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

163 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-26

Study Completion Date

2023-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prostate cancer is the second leading cause of cancer related deaths in the western world (National Cancer Institute, 2011). Prostate cancer diagnosis relates to significant psychological distress (Roesch et al, 2005; Hervouet et al, 2005). The management options available for men with localized prostate cancer typically offer similar survival rate and one treatment has not been determined more effective than other. Variance in severity, duration and frequency of side effects between treatments is considerable (National Cancer Institute, 2011). This can make the choice between management options challenging and distressing. Researches show that patients that are actively involved and provided with sufficient information have better health outcomes (Stewart, 1995).

The study involves implementing interactive, web-based decision-aid to assist men with localized prostate cancer with their decision regarding their prostate cancer management options. Participants will be randomized to standard-care (SC) and SC + interactive decision-aid (IDA). The SC group will meet with their urologist and receive and information brochure. In addition the IDA group will receive a website that includes a wealth of information (e.g., overview about prostate cancer, overview of different treatment options, pros and cons of different treatment options and a value clarification exercise that is designed to assist participants to weigh the risks and benefits of each prostate cancer management option).

The effectiveness of the intervention will be evaluated with questionnaires administered prior to randomization (baseline) and then again two weeks, one, three and six months after the randomization.

Aim 1. Evaluate the relative impact of SC versus SC + IDA on medical decision making. It is hypothesized that participants randomized to the SC + IDA arms will have improved decision making (e.g., reduced decisional conflict) and psychosocial outcomes (e.g., distress), compared to those randomized to SC only.

Aim 2. Identify mechanisms by which the interventions impact patient outcomes. It is hypothesized that: 1) improved decision making and psychosocial outcomes for the IDA arms will be mediated by increased knowledge; 2) participants who are undecided about the treatment decision and those that have information-seeking decision styles will benefit most from the decision-aid interventions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard Care

The control group will receive standard care for localized prostate cancer, i.e., information from their doctor and an information brochure.

Group Type NO_INTERVENTION

No interventions assigned to this group

Decision Aid + Standard Care

The intervention group will receive standard care and intervention that includes a website with the Decision Aid which covers the following:

1. An overview about prostate cancer;
2. An overview of different treatment options (e.g. surgery and active surveillance)
3. The pros and cons of different treatment options (e.g., physical, emotional, social).
4. A value clarification exercise that is designed to assist participants to weigh the pros and cons of each prostate cancer management option.

Group Type EXPERIMENTAL

Decision Aid for Men with Localized Prostate Cancer

Intervention Type OTHER

The intervention is an interactive decision aid aimed to assist newly diagnosed prostate cancer patients with their treatment management options.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Decision Aid for Men with Localized Prostate Cancer

The intervention is an interactive decision aid aimed to assist newly diagnosed prostate cancer patients with their treatment management options.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Newly diagnosed with localized prostate cancer.

Exclusion Criteria

* Reads and understands Icelandic
* Can give informed consent
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Icelandic Research Fund

UNKNOWN

Sponsor Role collaborator

The Icelandic Cancer Society

UNKNOWN

Sponsor Role collaborator

Reykjavik University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. Heiddis B Valdimarsdottir

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Heiddis B Valdimarsdottir, PhD

Role: PRINCIPAL_INVESTIGATOR

Reykjavik University

Birna Baldursdottir, PhD

Role: STUDY_DIRECTOR

Reykjavik University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Reykjavik University

Reykjavik, , Iceland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Iceland

References

Explore related publications, articles, or registry entries linked to this study.

Roesch SC, Adams L, Hines A, Palmores A, Vyas P, Tran C, Pekin S, Vaughn AA. Coping with prostate cancer: a meta-analytic review. J Behav Med. 2005 Jun;28(3):281-93. doi: 10.1007/s10865-005-4664-z.

Reference Type BACKGROUND
PMID: 16015462 (View on PubMed)

Hervouet S, Savard J, Simard S, Ivers H, Laverdiere J, Vigneault E, Fradet Y, Lacombe L. Psychological functioning associated with prostate cancer: cross-sectional comparison of patients treated with radiotherapy, brachytherapy, or surgery. J Pain Symptom Manage. 2005 Nov;30(5):474-84. doi: 10.1016/j.jpainsymman.2005.05.011.

Reference Type BACKGROUND
PMID: 16310621 (View on PubMed)

Stewart MA. Effective physician-patient communication and health outcomes: a review. CMAJ. 1995 May 1;152(9):1423-33.

Reference Type BACKGROUND
PMID: 7728691 (View on PubMed)

Berger O, Gronberg BH, Loge JH, Kaasa S, Sand K. Cancer patients' knowledge about their disease and treatment before, during and after treatment: a prospective, longitudinal study. BMC Cancer. 2018 Apr 3;18(1):381. doi: 10.1186/s12885-018-4164-5.

Reference Type BACKGROUND
PMID: 29614997 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

141490-052

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

VSN-18-127

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Focal Therapy for Prostate Cancer
NCT01802307 WITHDRAWN PHASE2
Characterization of Prostate Cancer With 3T MR
NCT00831142 ACTIVE_NOT_RECRUITING
Technologies to Improve QoL of Prostate Cancer
NCT06516276 NOT_YET_RECRUITING NA
Quality of Life in Prostate Cancer Patients
NCT04357925 ACTIVE_NOT_RECRUITING